University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.

Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

Despite alarming figures and trends, public awareness of alcohol as a carcinogen remains low.

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.

University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Matthew Brunner, MD, discusses the heterogeneity of relapsed multiple myeloma and the various symptoms that patients could experience.

Natalie S. Callander, MD, discusses the significance of the phase 3 ATLAS, phase 2 FORTE, and phase 2 MASTER trials in patients with multiple myeloma.

Natalie S. Callander, MD, discusses the potential benefits of referring patients with multiple myeloma to CAR T-cell therapy earlier in their disease course.

Matthew Brunner, MD, discusses how the phase 2 BMT CTN 1902 trial of anti-BCMA CAR T-cell therapy will attempt to address an area of unmet need in multiple myeloma.

Matthew Brunner, MD, discusses how to best approach the navigation of advanced imaging modalities in relapsed/refractory multiple myeloma.

Michael J. Fallon, MD, discusses supportive care considerations for patients with relapsed/refractory multiple myeloma.

Natalie S. Callander, MD, contextualizes the implications of the phase 3 ATLAS trial findings alongside other trials investigating maintenance regimens with triplet therapies in multiple myeloma.

UW Carbone’s expertise in head and neck cancer treatment and research are held in high esteem nationally, as evidenced by the National Cancer Institute awarding UW a Specialized Program of Research Excellence grant in 2016.

Electronic health record systems’ design, usability, and interoperability issues can hinder integration and use.

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.

Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.